Abbvie. M15-736. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients.
Axial Biotherapeutics. AB-4166. The effect of a dietary extract on GI tolerability and gut microbiome in a free-living subset of Parkinson’s patients.
E-Scape Biomarker. Biomarker Discovery in Parkinson’s Disease.
Sanofi. MOVES-PD: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.
Lundbeck. NOH402. RESTORE: A clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapy.
Retrotope. RT001. Compassionate Use Investigational New Drug. Expanded Access Protocol for the Treatment of Patients with Progressive Supranuclear Palsy with RT001.
Denali Therapeutics. DNL-0002. Denali Biomarker Study: A prospective collection of whole blood from patients with Parkinson’s disease and matched healthy volunteers at Parkinson’s Institute and Clinical Center for research purposes.
Parkinson’s Institute and Clinical Center. Gastrointestinal Natural History Study: A Two-Year Prospective Longitudinal Study using Quantitative and Qualitative Assessments to Define the Natural History of Gastrointestinal Symptoms in Patients with Parkinson’s Disease or at Risk for Developing the Motor Symptoms of Parkinson’s Disease.
National Parkinson Foundation: Parkinson’s Foundation Quality Improvement Initiative.
PPMI. Parkinson’s Progression Biomarkers Initiative.
Cala Health, Inc. ET-14. PROSPECT: Prospective study for Symptomatic Relief of Essential Tremor with Cala Therapy.
Neuroderm. ND0612L. A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease.
Hoffmann-La Roche. PASADENA. A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension.